Date: 2014-11-12
Type of information: Development agreement
Compound: non-invasive monitoring tools of the gut microbiome
Company: Abbvie (USA - IL) Enterome Bioscience (France)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement: development
Action mechanism:
Disease: Crohn's disease
Details: * On November 12, 2014, Enterome Bioscience, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a thorough understanding of the gut microbiome, announced that it has entered into a collaborative development agreement with AbbVie. The alliance is anchored around Enterome\'s proprietary metagenomic biomarker portfolio and technologies that may enable the development of novel diagnostic products to support personalized therapies and the development of new drugs in microbiome-related diseases. The companies will first collaborate to develop non-invasive monitoring tools of the gut microbiome in Crohn\'s disease. In this complementary partnership, Enterome\'s expertise in the microbiome space and AbbVie\'s extensive development capabilities in the Inflammatory Bowel Disease (IBD) space present an opportunity to co-develop a customized solution enabling routine monitoring of Crohn\'s disease by evaluating disease activity in order to make improved treatment decisions. \"The development of a new treatment paradigm in IBD depends on tight control that can only be achieved via accurate, routine disease activity measurement. Access to these data may allow the treating physician to prevent symptomatic relapse through early intervention and to avoid the potential over-use of therapeutics when not necessary. The ability to accurately analyze changes in the gut microbiome provides an ideal solution for the routine monitoring of IBD and other important diseases,\" said Pierre Belichard, Chief Executive Officer of Enterome. \"
Financial terms:
Latest news:
